Fibrinolytic therapy with recombinant tissue plasminogen activator in meningococcemia and purpura fulminans;Meningokokkensepsis und purpura fulminans. Erfolgreiche lysetherapie mit rekombinantem gewebeplasminogenaktivator

Monatsschrift fur Kinderheilkunde

Volumn 147, Issue 11, 1999, Pages 1010-1013

  Gessler, P ^a   Bachmann, D C G ^a   Pfenninger, J ^a  

^a NONE

Author keywords

Fibrinolysis; Meningococcemia; Purpura fulminans; Tissue plasminogen activator

Indexed keywords

ADRENALIN; ALTEPLASE; DOBUTAMINE; NADROPARIN; POLYGELINE;

ADOLESCENT; ARTICLE; BRAIN HEMORRHAGE; CASE REPORT; FIBRINOLYTIC THERAPY; FULMINATING PURPURA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MENINGOCOCCEMIA; SEPTIC SHOCK; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM; TREATMENT INDICATION;

EID: 0032758537     PISSN: 00269298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001120050532     Document Type: Article

References (27)

1. Adam D (1998) Aktuelles zur Meningokokken-Meningitis. Monatsschr Kinderheilkd 146:498-499
2. Aiuto LT, Barone SR, Cohen PS, Boxer RA (1997) Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Crit Care Med 25:1079-1082
3. Anderson MS, Glode MP, Smith AL (1998) Meningococcal disease. In: Feigin RD, Cherry JD (eds) Textbook of pediatric infectious diseases. Saunders, Philadelphia, pp 1143-1156
4. Andrew M, Michelson AD, Bovill E, Leaker M, Massicotte MP (1998) Guidelines for antithrombotic therapy in pediatric patients. J Pediatr 132:575-588
5. Brandtzaeg P, Joo GB, Brusletto B, Kierulf P (1990) Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 57:271-278
6. Farnoux C, Camard O, Pinquier D, Hurtaud-Roux M-F, Sebag G, Schlegel N, Beaufils F (1998) Recombinant tissue-type plasminogen activator therapy of thrombosis in 16 neonates. J Pediatr 133:137-140
7. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J (1993) Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104:882-888
8. Gerson WT, Dickerman JD, Bovill EG, Golden E (1993) Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate. Pediatrics 91:418-422
9. Girardin E, Grau GE, Dayer J-M, Roux-Lombard P, Lambert P-H (1988) Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 319:397-400
10. GUSTO investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673-682
11. Hathaway WW (1973) Heparin therapy in acute meningococcemia. J Pediatr 82:900-901
12. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group (1992) ISIS-3:a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 339:753-770
13. Leclerc F, Chenaud M, Delepoulle F, Diependaele JF, Martinot A, Hue V (1991) Prognostic value of C-reactive protein level in severe infectious purpura: A comparison with eight other scores. Crit Care Med 19:430-432
14. Levy M, Benson LN, Burrow PE, Bentur Y, Strong DK, Smith J (1991) Tissue plasminogen activator for the treatment of thromboembolism in infants and children. J Pediatr 118:467-472
15. Malley R, Huskins C, Kuppermann N (1996) Multivariable predictive models for adverse outcome of invasive meningococcal disease in children. J Pediatr 129:702-710
16. McManus ML, Churchwell KB (1993) Coagulopathy as a predictor of outcome in meningococcal sepsis and the systemic inflammatory response syndrome with purpura. Crit Care Med 21:706-711
17. Nadel S, De Munter C, Britto J, Habibi P, Levin M (1998) Comment to: Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans (letter). Crit Care Med 26:971-972
18. Peters M, Kerr S (1998) Comment to: Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans (letter). Crit Care Med 26:972-973 (letter)
19. Riedo FX, Plikaytis BD, Broome CV (1995) Epidemiology and prevention of meningococcal disease. Pediatr Infect Dis J 14:643-657
20. Rintala E, Seppälä O-P, Kotilainen P, Pettilä V, Rasi V (1998) Protein C in the treatment of coagulopathy in meningococcal disease. Crit Care Med 26:965-968
21. Van Deuren M, Van der Ven-Jongekrijg J, Bartelink AKM, Van Dalen R, Sauerwein RW, Van der Meer JWM (1995) Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. J Infect Dis 172:433-439
22. Van Deuren M, Neeleman C, Van't Hek LGFM, Van der Meer JWM (1998) A normal platelet count at admission in acute meningococcal disease does not exclude a fulminant course. Intensive Care Med 24:157-161
23. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T (1989) The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin-6, interleukin-1, and fatal outcome. J Exp Med 169:333-338
24. Weiner GM, Castle VP, DiPietro MA, Faix RG (1998) Successful treatment of neonatal arterial thromboses with recombinant tissue plasminogen activator. J Pediatr 133:133-136
25. Winter K, Noppeney C, Thom G, Runge K (1997) Rekombinanter Gewebe-Plasminogen-Aktivator in der Behandlung einer fulminanten Meningokokken-Sepsis. Klin Padiatr 209:380-383
26. Zenz W, Muntean W, Gallistl S, Zobel G, Grubbauer HM (1993) Recombinant tissue plasminogen activator treatment in two infants with fulminant meningococcemia. Pediatrics 96:144-148
27. Zenz W, Bodo Z, Zobel G, Franzens K, Fanconi S, Rettenbacher A (1998) Comment to: Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans (letter). Crit Care Med 1998:969-971